For patients with HF, using SGLT2 inhibitors with low SGLT2/SGLT1 selectivity had non-statistically lower risks of all-cause mortality than placebo, but the inhibitors with high selectivity did for CV death. The gene discussed is SLC5A2; the disease is hydrops fetalis.